Home / Metabolic Disease
Metabolic Disease
| 4 min read
Legal battles, FDA setbacks, billion-dollar bets, and more led the news this week.
| 4 min read
These late-stage therapies span obesity, diabetes, hypertension, and allergy care, offering new mechanisms and delivery formats that could reshape patient treatment.
| 4 min read
Eli Lilly’s oral orforglipron and Novo Nordisk’s higher-dose WeGovy could be approved on an extremely accelerated timeline. 
| 4 min read
The FDA’s National Priority Voucher program aims to cut standard review times from potentially years to months, raising questions about safety, access, and public health impact.
| 3 min read
Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease.
| 3 min read
A gene therapy targeting ANTIGPTL3 reduced cholesterol and triglyceride levels simultaneously.
| 5 min read
Explore the mechanisms, clinical applications, and future opportunities of GLP-1 receptor agonists in drug development and disease management.
| 6 min read
By combining 3D biofabrication with perfusable vasculature, researchers are paving the way for fully implantable organs.
| 7 min read
With blockbuster status secured, GLP-1 therapies face new questions about efficacy, delivery, and their role in treating multiple chronic diseases.
| 3 min read
The kidney structures replicate newborn-level maturity, enabling studies of complex disease features such as fibrosis and drug toxicity.
| 2 min read
Researchers showed that in rodent models, a glia-produced molecule could regulate weight loss and glucose metabolism without gastrointestinal symptoms.
| 2 min read
EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema.
